ClinicalTrials.gov API v2 · 登记更新· Novartis Pharmaceuticals·· 2 天前
行业资料：Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
AI 导读
原文摘录：The purpose of this 1-year open-label extension study is to characterize the longer-term safety and tolerability of DDY391 and to assess the durability of clinical response in participants with Psoriatic Arthritis (PsA) who have completed treatment in the
来源：ClinicalTrials.gov API v2 · 登记更新 · clinicaltrials.gov